Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Mental Health and Addiction
Published in: International Journal of Mental Health and Addiction 3/2018

Open Access 01-06-2018 | Original Article

Pregabalin Misuse and Abuse in Jordan: a Qualitative Study of User Experiences

Authors: Amneh Al-Husseini, Mayyada Wazaify, Marie Claire Van Hout

Published in: International Journal of Mental Health and Addiction | Issue 3/2018

Login to get access

Abstract

Pregabalin is currently approved for the treatment of epilepsy, generalized anxiety disorder, neuropathic pain, and fibromyalgia. A qualitative study was undertaken in Jordan, where concerns have been raised about its unprescribed availability in community pharmacies and thereby its abuse. Semi-structured interviews were conducted with all patients with a history of pregabalin use in two Jordanian addiction treatment centers. All were male patients aged 21–30 years (n = 11). The majority was poly-drug abusers and had a previous history of substance abuse (tramadol, Captagon, synthetic cannabinoids, and marijuana). Six key themes emerged from a content textual analysis which centered on pregabalin and other drugs; the pregabalin effect; poly-pharming and pregabalin intoxication; trajectories, patterns, and routes of administration; dependence and withdrawal; and sourcing of pregabalin. The study underscores the need for continued pharmacovigilance to manage and address suspected abuse, along with community pharmacist and patient education regarding abuse liability and related harms.
Literature
Albsoul-Younes, A., Wazaify, M., Yousef, A. M., & Tahaineh, L. (2010). Abuse and misuse of prescription and nonprescription drugs sold in community pharmacies in Jordan. Substance Use & Misuse, 45(9), 1319–1329.CrossRef
Babbie, E. R. (2010). The practice of social research (12th ed.p. 530). Wadsworth: Cengage Learning.
Baird, C. R., Fox, P., & Colvin, L. A. (2014). Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. European Addiction Research, 20(3), 115–118.CrossRefPubMed
Carrus, D., & Schifano, F. (2012). Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. Journal of Clinical Psychopharmacology, 32(6), 839–840.CrossRefPubMed
Casati, A., Sedefov, R., & Pfeiffer-Gerschel, T. (2012). Misuse of medicines in the European Union: a systematic review of the literature. European Addiction Research, 18(5), 228–245.CrossRefPubMed
Cooper, R. J. (2013). Over-the-counter medicine abuse—a review of the literature. Journal of Substance Use, 18(2), 82–107.CrossRefPubMed
Driot, D., Chicoulaa, B., Jouanjus, E., Dupouy, J., Oustric, S., & Lapeyre-Mestre, M. (2016). Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Thérapie, 71(6), 575–578.CrossRefPubMed
Drug Enforcement Administration, Department of Justice. (2005). Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Federal Register, 70(144), 43633.
Dum, J., Gramsch, C. H., & Herz, A. (1983). Activation of hypothalamic β-endorphin pools by reward induced by highly palatable food. Pharmacology Biochemistry and Behavior, 18(3), 443–447.CrossRef
Freynhagen, R., Backonja, M., Schug, S., Lyndon, G., Parsons, B., Watt, S., & Behar, R. (2016). Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs, 30, 1–10.CrossRef
Getto, C. J., Fullerton, D. T., & Carlson, I. H. (1984). Plasma immunoreactive beta-endorphin response to glucose ingestion in human obesity. Appetite, 5(4), 329–335.CrossRefPubMed
Grosshans, M., Lemenager, T., Vollmert, C., Kaemmerer, N., Schreiner, R., Mutschler, J., ... & Hermann, D. (2013). Pregabalin abuse among opiate addicted patients. European Journal of Clinical Pharmacology, 69(12), 2021–2025.
Haddad, L., Shotar, A., Umlauf, M., & Al-Zyoud, S. (2010). Knowledge of substance abuse among high school students in Jordan. Journal of Transcultural Nursing, 21(2), 143–150.CrossRefPubMed
Hernandez, S. H., & Nelson, L. S. (2010). Prescription drug abuse: insight into the epidemic. Clinical Pharmacology & Therapeutics, 88(3), 307–317.CrossRef
Holsti, O. R. (1969). Content analysis for the social sciences and humanities. Reading: Addison-Wesley.
Hughes, G. F., McElnay, J. C., Hughes, C. M., & McKenna, P. (1999). Abuse/misuse of non-prescription drugs. Pharmacy World & Science, 21(6), 251–255.CrossRef
Husserl, E. (1970). Logical investigation. New York: Humanities Press.
Jaber, D., Bulatova, N., Suyagh, M., Yousef, A. M., & Wazaify, M. (2015). Knowledge, attitude and opinion of drug misuse and abuse by pharmacy students: a cross-sectional study in Jordan. Tropical Journal of Pharmaceutical Research, 14(8), 1501–1508.CrossRef
Jensen, C., Forlini, C., Partridge, B., & Hall, W. (2016). Australian university students’ coping strategies and use of pharmaceutical stimulants as cognitive enhancers. Frontiers in Psychology, 7, 277.PubMedPubMedCentral
Johnson, B. A., Cloninger, C. R., Roache, J. D., Bordnick, P. S., & Ruiz, P. (2000). Age of onset as a discriminator between alcoholic subtypes in a treatment-seeking outpatient population. The American Journal on Addictions, 9(1), 17–27.CrossRefPubMed
Kampov-Polevoy, A., Garbutt, J. C., & Janowsky, D. (1997). Evidence of preference for a high-concentration sucrose solution in alcoholic men. American Journal of Psychiatry, 154(2), 269–270.CrossRefPubMed
Lessenger, J. E., & Feinberg, S. D. (2008). Abuse of prescription and over-the-counter medications. The Journal of the American Board of Family Medicine, 21(1), 45–54.CrossRefPubMed
Millar, J., Sadasivan, S., Weatherup, N., & Lutton, S. (2013). Lyrica nights—recreational pregabalin abuse in an urban emergency department. Emergency Medicine Journal, 30(10), 874–874.CrossRef
Palamar, J. J., & Barratt, M. J. (2016). Synthetic cannabinoids: undesirable alternatives to natural marijuana. The American Journal of Drug and Alcohol Abuse, 42(4), 371–373.CrossRefPubMedPubMedCentral
Papazisis, G., & Tzachanis, D. (2014). Pregabalin’s abuse potential: a mini review focusing on the pharmacological profile. International Journal of Clinical Pharmacology and Therapeutics, 52(8), 709–716.CrossRefPubMed
Papazisis, G., Garyfallos, G., Sardeli, C., & Kouvelas, D. (2013). Pregabalin abuse after past substance-seeking behavior. International Journal of Clinical Pharmacology and Therapeutics, 51(5), 441–442.CrossRefPubMed
Schifano, F., D’Offizi, S., Piccione, M., Corazza, O., Deluca, P., Davey, Z., ... & Mannonen, M. (2011). Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychotherapy and Psychosomatics, 80(2), 118–122.
Schjerning, O., Rosenzweig, M., Pottegård, A., Damkier, P., & Nielsen, J. (2016). Abuse potential of pregabalin. CNS Drugs, 30(1), 9–25.CrossRefPubMed
Schwan, S., Sundström, A., Stjernberg, E., Hallberg, E., & Hallberg, P. (2010). A signal for an abuse liability for pregabalin—results from the Swedish spontaneous adverse drug reaction reporting system. European Journal of Clinical Pharmacology, 66(9), 947–953.CrossRefPubMed
Spigset, O., & Westin, A. A. (2013). Detection times of pregabalin in urine after illicit use: when should a positive specimen be considered a new intake? Therapeutic Drug Monitoring, 35(1), 137–140.CrossRefPubMed
Van Hout, M. C., & Hearne, E. (2017). User experiences of development of dependence on the synthetic cannabinoids, 5f-AKB48 and 5F-PB-22, and subsequent withdrawal syndromes. International Journal of Mental Health and Addiction, 15(3), 565–579.CrossRef
Van Hout, M. C., & Wells, J. (2016). Is Captagon (fenethylline) helping to fuel the Syrian conflict? Addiction, 111(4), 748–749.CrossRefPubMed
Wazaify, M., Abood, E., Tahaineh, L., & Albsoul-Younes, A. (2016). Jordanian community pharmacists’ experience regarding prescription and nonprescription drug abuse and misuse in Jordan—an update. Journal of Substance Use, 1–6.
Yazdi, K., Hemetsberger, U., & Baier, C. (2015). Pregabalin abuse of bebzodiazepine and alcohol addicted patient. Psychiatria Danubina, 27(3), 279.
Metadata
Title
Pregabalin Misuse and Abuse in Jordan: a Qualitative Study of User Experiences
Authors
Amneh Al-Husseini
Mayyada Wazaify
Marie Claire Van Hout
Publication date
01-06-2018
Publisher
Springer US
Published in
International Journal of Mental Health and Addiction / Issue 3/2018
Print ISSN: 1557-1874
Electronic ISSN: 1557-1882
DOI
https://doi.org/10.1007/s11469-017-9813-4

Other articles of this Issue 3/2018

International Journal of Mental Health and Addiction 3/2018 Go to the issue

Original Article

Patient and Caregiver Perspectives on Ethical Issues in Mental Health Care: an Exploratory Study from India

Original Article

An Exploratory Study of the Impacts of Gambling on Affected Others Accessing a Social Service

Brief Report

Alcohol Use and Related Problem Behavior: a Survey Among Russian Federation and Israeli Female University Students

OriginalPaper

Sensitivity of the ASAM Criteria to Psychiatric Need

Original Article

Protection of Privacy of Information Rights among Young Adults with Developmental Disabilities

Original Article

Development of a Psychoeducational Intervention for Community-Based Care Facilities to Substance Use Disorders in Mexico